ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Oncology

Recce Pharmaceuticals Initiates Phase I/II Rapid Infusion Clinical Trial of RECCE® 327 for UTI at Scientia Clinical Research

Thursday, July 27, 2023

Reece Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has made an exciting announcement regarding the progress of its Phase I/II clinical trial for a new class of synthetic anti-infectives targeting urinary tract infections (UTIs). Both male and female subjects have been successfully dosed in the trial, which is being conducted at Scientia Clinical Research in Sydney, New South Wales.

To expedite patient recruitment and expand the trial's reach, Reece Pharmaceuticals added Scientia Clinical Research as a trial site, a decision that has proven fruitful. Dosing at the site has progressed ahead of schedule, with subjects receiving R327 through intravenous administration at faster infusion rates of 2,500mg.

The trial is proceeding well and is on track to meet its primary endpoints. The remaining subjects are set to be dosed at Scientia Clinical Research this week, with data read-outs expected in the second half of 2023. This milestone marks a significant advancement in the development of R327 as a potential treatment for urinary tract infections.

Oliver Healthcare Packaging Pharmaceutical SolutionsThermoFisher - Mastering API production at every scaleFuture Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing Pharma